相关实验视频

Updated: Jul 20, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

在早产婴儿中使用表面活性剂的临床决策门:系统性审查和网络元分析

Viraraghavan Vadakkencherry Ramaswamy¹, Tapas Bandyopadhyay², Thangaraj Abiramalatha³

¹Department of Neonatology, Ankura Hospital for Women and Children, Hyderabad, India.

EClinicalMedicine

|August 4, 2023

概括

表面活性剂可以帮助30周以下的早产婴儿患有呼吸困扰综合征 (RDS),如果他们需要40%的氧气. 这一发现基于有限的证据,表明早期干预的潜在门.

科学领域:

新生儿医学新生儿医学
呼吸系统生理学呼吸系统生理学
基于证据的医学基于证据的医学.

背景情况:

呼吸应急综合征 (RDS) 是早产新生儿的常见疾病.
在RDS中施用表面活性剂的最佳时间仍在争论中.
引导表面活性剂治疗的临床标准需要进一步定义.

研究的目的:

系统地审查随机对照试验 (RCT).
确定给RDS的早产新生儿施用表面活性剂的最佳临床标准.
进行网络元分析,以比较各种表面活性剂的管理策略.

主要方法:

一个系统的审查和58个RCT的贝叶斯随机效应网络元分析 (NMA).
在Medline,Embase,CENTRAL和CINAHL数据库中进行了搜索.
主要结局是需要在7天内进行侵入性机械通风 (IMV).

主要成果:

在≤30周的新生儿中,动脉/气囊氧张力比<0.36 (FiO2: 37-55%) 与IMV风险降低有关 (确定性非常低).
与救援治疗相比,FiO240-45%的表面活性剂可能会降低死亡率 (确定性非常低).
对于≤30周的新生儿,如果需要FiO2≥40%,可以考虑使用表面活性剂.

结论:

表面活性剂的使用可能对早产新生儿 (≤30周) 有RDS需要FiO2≥40%有益.
证据的确定性很低,需要谨慎的解释.
需要对较低的FiO2值和肺超声指导进行进一步的研究.

关键词:

新生儿新生儿新生儿过早生育的孩子.在 RDS RDS RDS 中.表面活性剂是一种表面活性剂.

更多相关视频

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus

Published on: March 6, 2019

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

相关概念视频

Breathing

Breathing

The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...